Table 2.
Reported cases of MALT lymphoma of the minor salivary glands in Sjögren’s syndrome patients
| Author | Year | No. of cases | Age | Sex | Oral location | Other locations | Risk factors | Treatment | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
| Speight et al. [23] | 1994 | 4 | NR | NR | Lipa | Stomach | NR | NR | NR |
| NR | NR | Lipa | Palate | NR | NR | NR | |||
| NR | NR | Lipa | Cervical lymph nodes | NR | NR | NR | |||
| NR | NR | Lipa | Cervical lymph nodes | NR | NR | NR | |||
| Van Mello et al. [24] | 2005 | 3 | 53 | F | Lipb | Possibly chest area | Non-blanching purpuric lesions on the lower limbs, C4 low | NR | NR |
| 51 | F | Lipb | NR |
Intermittent swollen parotids, raised levels of total protein, IgG, IgA, IgM, while C4 levels and white blood cell count were decreased |
NR | NR | |||
| 55 | Lipa | NR | Intermittent swelling of the parotid gland |
Leukeran (4 mg daily) and prednisone 20 mg/day |
NR | ||||
| Pijpe et al. [25] | 2005 | 1 | 42 | F | Hard palateb |
Right Parotid
10 years earlier neck lymph nodes |
Increased IgG | Weekly, course of 4 infusions of rituximab | NS, no recurrence |
| Sakuma et al. [26] | 2006 | 1 | 70 | F | Hard palatea | - | - | Self regression | 38 months, no recurrence |
| Keszler et al. [27] | 2012 | 1 | 60 | F | Lipa | - | - | Watch and wait |
Evaluation performed every 6 months during the first year and then, once a year, no recurrence |
| Shwetha et al. [28] | 2014 | 1 | 62 | F |
Upper and lower lipb |
- | - | Watch and wait | NS, no recurrence |
| Present case | 2017 | 1 | 64 | F |
Hard palatea |
Stomach; spleen; bone marrow | CD4 + T lymphocytopenia, neutropenia, high serum β2 microglobulin, low serum IgM levels |
Refused treatment for 1 year (Rituximab + Fludarabine) |
2 years, no recurrence |
aMALT lymphoma diagnosed after Sjögren’s syndrome initial diagnosis.
bMALT lymphoma diagnosed simultaneously with Sjögren’s syndrome.
NR = not reported; F = female; NS = not specified.